Assessing Celcuity (CELC) Valuation After Strong Recent Returns And Optimistic Growth Forecasts

Why Celcuity (CELC) is Drawing Fresh Attention

Celcuity (CELC) has come into focus after recent share price moves and its role as a clinical-stage biotechnology company working on targeted therapies for solid tumors, including advanced breast and prostate cancers.

See our latest analysis for Celcuity.

The current US$115.0 share price comes after a 6.2% 7 day share price return and an 11.9% 90 day share price return. The 1 year total shareholder return is very large, hinting that recent moves are part of a much stronger longer term trend.

If Celcuity’s run has you thinking about where else strong interest is building in healthcare, this is a good moment to check out 32 healthcare AI stocks as a fresh set of ideas.

With Celcuity posting a very large 1-year total shareholder return and trading close to the US$116.70 analyst price target, the key question is whether the current valuation still leaves a buying opportunity or if markets are already pricing in future growth.

Most Popular Narrative: 1.5% Undervalued

Celcuity’s widely followed narrative pegs fair value at $116.70, only slightly above the last close at $115.00, so the story really rests on future execution.

Celcuity currently has no revenue. Analysts are forecasting revenue to reach $607.1 million by March 2029. As a pre-revenue company, Analysts expect Celcuity to achieve a profit margin of 25.1% in 3 years time. Analysts expect earnings to reach $152.4 million (and earnings per share of $2.49) by about March 2029, up from -$162.7 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $351.8 million in earnings, and the most bearish expecting $127.2 million.

Read the complete narrative.

Curious how a pre revenue biotech gets to that kind of profit profile in just a few years? The narrative leans heavily on growth, margins and a future earnings multiple that is far higher than what the broader biotech sector currently trades on. If you want to see exactly which assumptions power that fair value, the full story is worth a look.

Result: Fair Value of $116.70 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this story can change quickly if gedatolisib data disappoints or if regulators slow approvals, which would push out revenue timing and extend current losses.

Find out about the key risks to this Celcuity narrative.

Another View: High Price Tag On A Book Value Basis

If you step away from future earnings forecasts and just look at today’s balance sheet, Celcuity trades on a P/B of 45.5x versus 13.1x for direct peers and 2.7x for the wider US biotechs group. That is a steep premium, so how comfortable are you paying so far above the pack?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

The mix of optimism and concern around Celcuity is clear. If you want to move quickly and form your own view, check out 2 key rewards and 2 important warning signs.

Ready to compare more opportunities?

If Celcuity has sharpened your focus, do not stop here, a broader watchlist of quality ideas can help you spot opportunities you might otherwise miss.

• Target stronger fundamentals by reviewing companies in our solid balance sheet and fundamentals stocks screener (41 results) and see which ones match your risk comfort and time horizon.
• Hunt for potential value by scanning the 50 high quality undervalued stocks and checking which businesses line up with your own expectations and research.
• Strengthen your income ideas by reviewing companies in the 16 dividend fortresses so you are not relying on just a handful of names.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com